Red blood cell-tumor cell interactions promote tumor cell progression
Thais Pereira‐Veiga(Universität Hamburg), Clotilde Costa(Instituto de Investigación Sanitaria de Santiago), Rafael López‐López(Universidade de Santiago de Compostela), Julian Götze(Universität Hamburg), Katrin Lamszus(Universität Hamburg), Sabine Windhorst(Universität Hamburg), Miriam González-Conde(Instituto de Investigación Sanitaria de Santiago), L. Muinelo-Romay(Universidade de Santiago de Compostela), Klaus Pantel(Universität Hamburg), Celso Yáñez-Gómez(Instituto de Investigación Sanitaria de Santiago), Bente Siebels(Universität Hamburg), Joao Gorgulho(Universität Hamburg), Nadine Heuer‐Olewinski(German Center for Lung Research), Alexandra Cortegoso(Instituto de Investigación Sanitaria de Santiago), Martin Reck(German Center for Lung Research), Christine Blechner(Universität Hamburg), K. Meißner(Universität Hamburg), Ana B. Dávila‐Ibáñez(Instituto de Investigación Sanitaria de Santiago), Alexander T. Bauer(Heidelberg University), Pablo Cabezas‐Sainz(Universidade de Santiago de Compostela), Teresa Curiel(Instituto de Investigación Sanitaria de Santiago), Mustafa Abdo(Heidelberg University), Juan Cueva(Instituto de Investigación Sanitaria de Santiago), Alicia Abalo(Universidade de Santiago de Compostela), Harriet Wikman(Universität Hamburg), Milena Schmidt(German Center for Lung Research), Carmela Rodríguez(Instituto de Investigación Sanitaria de Santiago), Luis León‐Mateos(Instituto de Investigación Sanitaria de Santiago), Sven Peine(Universität Hamburg), Sabine Vidal‐y‐Sy(Universität Hamburg), Laura Sánchez‐García(Universidade de Santiago de Compostela), Marta Carmona(Instituto de Investigación Sanitaria de Santiago), Aleksi Pekkarinen(Universität Hamburg), Maider Santos(Universidade de Santiago de Compostela), Patricia Palacios(Instituto de Investigación Sanitaria de Santiago), Christian Mess(Universität Hamburg), Ayham Moustafa(Universität Hamburg), Carmen Abuín(Instituto de Investigación Sanitaria de Santiago)
Cited by 7
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
|Journal of Clinical Oncology|2009|1.5k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
|Annals of Oncology|2010|644
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
|Science Advances|2018|614